Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis
- 1 January 2006
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 38 (10) , 904-908
- https://doi.org/10.1080/00365540600664076
Abstract
We investigated the distribution of moxifloxacin in the interstitial space of normal and infected subcutaneous tissue in patients with spinal cord injury and decubitus ulcers using in vivo microdialysis. Drug concentrations achieved in serum, saliva, normal and infected tissues showed approximately parallel time profiles. The interstitial tissue fluids reached bactericidal levels for common bacteria found in infected skin lesions. Our findings suggest that moxifloxacin exhibits good and similar penetration into the interstitial space fluid in normal subcutaneous tissue and infected decubitus ulcers in patients with spinal cord injury.Keywords
This publication has 18 references indexed in Scilit:
- Spinal Cord Injury and Pressure UlcersNursing Clinics of North America, 2005
- Effects of Enteral Feeding on the Oral Bioavailability of Moxifloxacin in Healthy VolunteersClinical Pharmacokinetics, 2005
- Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Distribution in TissueAntimicrobial Agents and Chemotherapy, 2004
- MoxifloxacinDrugs, 2004
- Newer Treatment Options for Skin and Soft Tissue InfectionsDrugs, 2004
- Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human TrialsAnnals of Pharmacotherapy, 2003
- Penetration of Moxifloxacin into Healthy and Inflamed Subcutaneous Adipose Tissues in HumansAntimicrobial Agents and Chemotherapy, 2003
- Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing RatesAnnals of Pharmacotherapy, 2003
- Effects of Blood Flow on the in Vivo Recovery of a Small Diffusible Molecule by Microdialysis in Human SkinThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Impaired target site penetration of β -lactams may account for therapeutic failure in patients with septic shockCritical Care Medicine, 2001